NCT00503061CompletedNot Applicable
A Pharmaceopidemiological Study in Patients Who Use Symbicort Turbuhaler as Maintenance and Reliever Therapy (Symbicort SMART) Capturing Over Use and Under Use Via the General Practice Research Database
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 1,000
- Locations
- 1
Study Overview
Brief Summary
To investigate how common it is that patients using Symibort SMART take high average daily doses that are not considered appropriate by their physician (overuse) or are hospitalised due to their asthma at least partly due to underuse.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Asthma diagnosis, patient registered with the prescribing physician for at least one year before the qualifying prescription of Symbicort, prescription of Symbicort SMART after UK launch of the concept
Exclusion Criteria
- Not provided
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Symbicort SMART (Symbicort Maintenance And Reliever Therapy)AsthmaNCT00523679AstraZeneca2,000
Completed
Phase 1
Safety and Tolerability Study of SHP626 in Overweight and Obese AdultsNon-Alcoholic SteatohepatitisNCT02287779Mirum Pharmaceuticals, Inc.84
Completed
Phase 3
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPDChronic Obstructive Pulmonary DiseaseNCT00419744AstraZeneca1,200
Completed
Phase 3
An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent AsthmaAsthmaNCT00419757AstraZeneca558
Completed
Not Applicable
Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in FranceAsthmaNCT00812357AstraZeneca579